Granted Patent
B2
US 12,303,571 · App. 17/373,987 · Granted May 20, 2025
Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
Inventors:
Robert Yongxin Zhao (Lexington, MA); Qingliang Yang (Hangzhou, CN); Yuanyuan Huang (Hangzhou, CN); Shun Gai (Hangzhou, CN); Linyao Zhao (Hangzhou, CN); Hangbo Ye (Hangzhou, CN); Huihui Guo (Hangzhou, CN); Qianqian Tong (Hangzhou, CN); Minjun Cao (Hangzhou, CN); Junxiang Jia (Hangzhou, CN); Chengyu Yang (Hangzhou, CN); Wenjun Li (Hangzhou, CN); Xiaomai Zhou (Hangzhou, CN); Hongsheng Xie (Hangzhou, CN); Chen Lin (Hangzhou, CN); Zhixiang Guo (Hangzhou, CN); Zhicang Ye (Hangzhou, CN)
Assignee:
HANGZHOU DAC BIOTECH CO., LTD.
A61K49/0058A61K47/68031A61K47/68033A61K47/68035A61K47/6809A61K47/6829A61K47/6889A61K49/0032A61K49/0043C07D417/12C07D417/14C07D498/18C07D513/22C07D519/00A61K31/194A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
Claims (25)
1. A compound having a structure of formula (III)
wherein:
represents either a single bond or a double bond;
Cb is a cell-binding agent selected from the group consisting of an antibody, a protein and a peptide;
X 1 and X 2 are independently absent or selected from the group consisting of NH; NHNH; N(R 3 );
N(R 3 )N(R 3 ′); O; S; B(R 3 ); Si(R 3 )N(R 3 ′); P(O)(R 3 ); C 1 -C 8 of alkyl; C 2 -C 8 of heteroalkyl, alkylcycloalkyl, or heterocycloalkyl; C 3 -C 8 of aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; 1-8 amino acids; wherein R 3 and R 3 , are independently H; C 1 -C 8 of alkyl; C 2 -C 8 of heteroalkyl, alkylcycloalkyl, or heterocycloalkyl; C 3 -C 8 of aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; C 1 -C 8 of esters, ether, or amide; polyethyleneoxy unit of formula (OCH 2 CH 2 ) p or (OCH 2 CH(CH 3 )) p , wherein p is an integer from 0 to about 1000, and a combination thereof;
R 1 and R 2 are independently one or more, or repeating, or a combining thereof, of the following components:
natural or unnatural peptides containing 1-20 amino acids;
m 1 and m 2 are independently an integer from 1 to 30;
n is an integer from 1 to 30; and
Z 1 is a function group that enables the compound to react with a cytotoxic drug, to form a disulfide, thioether, thioester, peptide, hydrazone, ether, ester, carbamate, carbonate, secondary, tertiary, or quarter amine, imine, cycloheteroalkyl, heteroaromatic, alkoxime or amide bond.
2. The compound of claim 1 , wherein the cell-binding agent is an antibody, full-length antibodies, polyclonal antibodies, monoclonal antibodies, dimer antibodies, multimer antibodies, multispecific antibodies, bispecific or trispecific antibodies, a single chain antibody, an antibody fragment that binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment that binds the target cell, a chimeric antibody, a chimeric antibody fragment that binds to the target cell, a domain antibody, a domain antibody fragment that binds to the target cell, a resurfaced antibody, a resurfaced single chain antibody, or a resurfaced antibody fragment that binds to the target cell, a humanized antibody or a resurfaced antibody, a humanized single chain antibody, or a humanized antibody fragment that binds to the target cell, anti-idiotypic antibodies, CDR's, diabody, triabody, tetrabody, miniantibody, small immune protein or large molecular weight protein.
3. The compound of claim 1 , wherein the cell-binding agent is an antibody, a protein or a peptide that is able to target against a tumor cell, a virus infected cell, a microorganism infected cell, a parasite infected cell, an autoimmune disease cell, an activated tumor cells, a myeloid cell, an activated T-cell, an affecting B cell, or a melanocyte.
4. The compound of claim 1 , wherein the cell-binding agent is an antibody, a protein or a peptide that is able to target against any one of the following antigens or receptors: CD3, CD4, CD5, CD6, CD7, CD8, CD9, CD10, CD11a, CD11b, CD11c, CD12w, CD14, CD15, CD16, CDw17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD51, CD52, CD53, CD54, CD55, CD56, CD58, CD59, CD61, CD62E, CD62L, CD62P, CD63, CD66, CD68, CD69, CD70, CD72, CD74, CD79, CD79a, CD79b, CD80, CD81, CD82, CD83, CD86, CD87, CD88, CD89, CD90, CD91, CD95, CD96, CD98, CD100, CD103, CD105, CD106, CD109, CD117, CD120, CD125, CD126, CD127, CD133, CD134, CD135, CD137, CD138, CD141, CD142, CD143, CD144, CD147, CD151, CD147, CD152, CD154, CD156, CD158, CD163, CD166, CD168, CD174, CD180, CD184, CDw186, CD194, CD195, CD200, CD200a, CD200b, CD209, CD221, CD227, CD235a, CD240, CD262, CD271, CD274, CD276, CD303, CD304, CD309, CD326, 4-1BB, 5AC, 5T4 trophoblast glycoprotein, TPBG, 5T4, Wnt-activated inhibitory factor 1 or WAIF1, adenocarcinoma antigen, AGS-5, AGS-22M6, activin receptor-like kinase 1, AFP, AKAP-4, ALK, alpha intergrin, alpha v beta6, amino-peptidase N, amyloid beta, androgen receptor, angiopoietin 2, angiopoietin 3, annexin A1, anthrax toxin protective antigen, anti-transferrin receptor, AOC3, B7-H3, Bacillus anthracis anthrax, BAFF, BCMA, B-lymphoma cell, bcr-abl, bombesin, BORIS, C5, C242 antigen, CA125, CA-IX, CALLA, CanAg, canis lupus familiaris IL31, carbonic anhydrase IX, cardiac myosin, CCL11, CCR4, CCR5, CD3E, CEA, CEACAM3, CEACAM5, CFD, Ch4D5, cholecystokinin 2, CLDN18, clumping factor A, cMet, CRIPTO, FCSF1R, CSF2 colony stimulating factor 2, and granulocyte-macrophage colony-stimulating factor, CSP4, CTLA4, CTAA16.88 tumor antigen, CXCR4, C-X-C chemokine receptor type 4, cyclic ADP ribose hydrolase, cyclin B1, CYP1B1, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, DLL4, DPP4, DR5, E. coli shiga toxin type-1, E. coli shiga toxin type-2, ED-B, EGFL7, EGFR, EGFRII, EGFRvIII, endoglin, endothelin B receptor, endotoxin, EpCAM, EphA2, episialin, ERBB2, ERBB3, ERG, Escherichia coli , ETV6-AML, FAP, FCGR1, alpha-fetoprotein, fibrin II, beta chain, fibronectin extra domain-B, FOLR, folate receptor alpha, folate hydrolase, Fos-related antigen 1F protein of respiratory syncytial virus, frizzled receptor, fucosyl GM1, GD2 ganglioside, G-28, GD3 idiotype, globoH, glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor α-chain, growth differentiation factor 8, GP100, GPNMB, GUCY2C guanylate cyclase 2C, guanylyl cyclase C, intestinal guanylate cyclase, guanylate cyclase-C receptor, and heat-stable enterotoxin receptor, heat shock proteins, hemagglutinin, hepatitis B surface antigen, hepatitis B virus, HER1, HER2, HER2/neu, HER3, IgG4, HGF/SF, HHGFR, HIV-1, histone complex, HLA-DR, HLA-DR10, HLA-DRB, HMWMAA, human chorionic gonadotropin, HNGF, human scatter factor receptor kinase, HPV E6/E7, Hsp90, hTERT, ICAM-1, idiotype, IGF1R, IGHE, IFN-γ, influenza hemagglutinin, IgE, IgE Fc region, IGHE, IL-1, IL-2 receptor, IL-4, IL-5, IL-6, IL-6R, IL-9, IL-10, IL-12, IL-13, IL-17, IL-17A, IL-20, IL-22, IL-23, IL31RA, ILGF2, integrins α4, α IIb β 3 , ανβ3, α 4 β 7 , α5β1, α6β4, α7β7, αIIβ3, α5β5, and ανβ5, interferon gamma-induced protein, ITGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, legumain, Lewis-Y antigen, LFA-1, LHRH, LINGO-1, Lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGE A1, MAGE A3, MAGE 4, MART1, MCP-1, MIF macrophage migration inhibitory factor, or glycosylation-inhibiting factor, MS4A1, MSLN, MUC1 mucin 1, or polymorphic epithelial mucin, MUC1-KLH, MUC16, MCP1, melanA/MART1, ML-IAP, MPG, MS4A1, MYCN, myelin-associated glycoprotein, myostatin, NA17, NARP-1, NCA-90, Nectin-4, NGF, neural apoptosis-regulated proteinase 1, NOGO-A, notch receptor, nucleolin, Neu oncogene product, NY-BR-1, NY-ESO-1, OX-40, OxLDL, OY-TES1, P21, p53 nonmutant, P97, Page4, PAP, paratope of anti-(N-glycolylneuraminic acid), PAX3, PAX5, PCSK9, PDCD1, PDGF-Ra, PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, platelet-derived growth factor receptor beta, phosphate-sodium co-transporter, PMEL 17, polysialic acid, proteinase3, prostatic carcinoma, phosphatidylserine, prostatic carcinoma cells, Pseudomonas aeruginosa , PSMA, PSA, PSCA, rabies virus glycoprotein, RHD, rhesus factor, RANKL, RhoC, Ras mutant, RGS5, ROBO4, respiratory syncytial virus, RON, ROR1, sarcoma translocation breakpoints, SART3, sclerostin, SLAMF7, selectin P, SDC1, sLe(a), somatomedin C, SIP, somatostatin, sperm protein 17, SSX2, STEAP1, STEAP2, STn, TAG-72, survivin, T-cell receptor, T cell transmembrane protein, TEM1, TENB2, tenascin C, TGF-α, TGF-β, TGF-β1, TGF-β2, Tie, Tie2, TIM-1, Tn, TNF, TNF-α, TNFRSF8, TNFRSF10B, TNFRSF-13B, TPBG, TRAIL-R1, TRAILR2, tumor-associated calcium signal transducer 2, tumor specific glycosylation of MUC1, TWEAK receptor, TYRP1, TRP-2, Tyrosinase, VCAM-1, VEGF, VEGF-A, VEGF-2, VEGFR-1, VEGFR2, or vimentin, WT1, XAGE 1, or cells expressing any insulin growth factor receptors, or any epidermal growth factor receptors.
5. The compound of claim 3 , wherein the tumor cell is selected from the group consisting of lymphoma cells, myeloma cells, renal cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, none small-cell lung cancer cells, testicular cancer cells, malignant cells, and any cells that grow and divide at an unregulated, quickened pace to cause a cancer.
6. The compound of claim 1 , wherein m 1 and m 2 are independently an integer from 1 to 10.
7. The compound of claim 1 , wherein R 1 or R 2 is cleavable by a protease.
8. The compound of claim 1 , wherein Z 1 comprises at least one of thiol, disulfide, amino, carboxyl, aldehyde, ketone, maleimido, haloacetyl, hydrazine, alkoxyamino, or hydroxy.
9. The compound of claim 1 , wherein Z 1 comprises at least one of N-hydroxysuccinimide ester, p-nitrophenyl ester, dinitrophenyl ester, pentafluorophenyl ester, carboxylic acid chloride, carboxylic acid anhydride, pyridyldisulfide, nitropyridyldisulfide, maleimide, haloacetate, methylsulfonephenyloxadiazole, amine, alkoxyamine, hydrazine, acyloxylamine, hydrazide, or alkyne.
10. The compound of claim 1 , wherein Z 1 is
wherein X 1 ′ is F, Cl, Br, I or Lv 3 ; X 2 ′ is O, NH, N(R 1 ), or CH 2 ; R 3 and R 5 are H, R 1 , aromatic, heteroaromatic, or aromatic group wherein one or several H atoms are replaced independently by —R, -halogen, —OR 1 , —SR 1 , —NR 1 R 2 , —NO 2 , —S(O)R 1 , —S(O) 2 R 1 , or —COOR 1 ; Lv 3 is a leaving group selected from the group consisting of methanesulfonyl, toluenesulfonyl, trifluoromethyl-sulfonyl, trifluoromethylsulfonate, nitrophenoxyl, N-succinimidyloxyl, phenoxyl; dinitrophenoxyl; pentafluorophenoxyl, tetrafluorophenoxyl, trifluorophenoxyl, difluorophenoxyl, monofluorophenoxyl, pentachlorophenoxyl, 1H-imidazole-1-yl, chlorophenoxyl, dichlorophenoxyl, trichlorophenoxyl, tetrachlorophenoxyl, N-(benzotriazolyl) oxyl, 2-ethyl-5-phenylisoxazolium-yl, phenyloxadiazol-yl, oxadiazol-yl, wherein R 1 and R 2 are the same defined in claim 1 , or an intermediate molecule generated from any of above with a condensation reagent for peptide coupling reactions or for Mitsunobu reactions.
11. A method of preparing a compound of formula (II), wherein the method comprises reacting the compound of claim 1 with a Drug 1 -containing compound:
wherein Drug 1 represents a cytotoxic agent or a drug, n is an integer of 1 to 30, and Cb, R 1 , R 2 , X 1 , X 2 , m 1 , m 2 and n are defined the same as in claim 1 .
12. The method of claim 11 , wherein the Drug 1 -containing compound comprises a hydroxyl group, thiol group or amino group.
13. The method of claim 11 , wherein the Drug 1 -containing compound is Drug 1 -OH, Drug 1 -NH 2 , Drug 1 -CO—NH—NH 2 , or Drug 1 -O—NH 2 .
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 14, 2021
From: SUZHOU M-CONJ BIOTECH CO., LTD.
To: HANGZHOU DAC BIOTECH CO., LTD.
Reel/Frame 056850/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 13, 2021
From: ZHAO, ROBERT YONGXIN; YANG, QINGLIANG; HUANG, YUANYUAN; GAI, SHUN; ZHAO, LINYAO; YE, HANGBO; GUO, HUIHUI; TONG, QIANQIAN; CAO, MINJUN; JIA, JUNXIANG; YANG, CHENGYU; LI, WENJUN; ZHOU, XIAOMAI; XIE, HONGSHENG; LIN, CHEN; GUO, ZHIXIANG; YE, ZHICANG
To: SUZHOU M-CONJ BIOTECH CO., LTD.; HANGZHOU DAC BIOTECH CO., LTD.
Reel/Frame 056836/0114 →
Continuity (2)
Continuation
16074981
References Cited (328)
US 9839687B2
· Zhao
· 2017
[cited by applicant]
WO 2005037992A2
· 2005
[cited by applicant]
WO 2014009774A1
· 2014
[cited by applicant]
WO WO2014197854A1
· 2014
[cited by examiner]
WO 2015151080A2
· 2015
[cited by applicant]
WO 2015151081A2
· 2015
[cited by applicant]
WO 2015155753A2
· 2015
[cited by applicant]
Office Action issued on Mar. 16, 2023, by the U.S. Patent and Trademark Office in U.S. Appl. No. 17/093,184, U.S. Patent and Trademark Office, Alexandria, VA. (7 pages).
[cited by applicant]
Thiele ,“2-Butynedioic acid”, 1910, 1 page.
[cited by applicant]
Examination Report No. 1 issued on Sep. 28, 2022, by the Australian Patent Office in corresponding Australian Patent Application No. 2021266317. (4 pages).
[cited by applicant]
Office Action issued on Oct. 5, 2022, by the U.S. Patent and Trademark Office in related U.S. Appl. No. 17/093,184. (7 pages).
[cited by applicant]
Office Action (Notice of acceptance for patent application) issued Sep. 29, 2023, by the Australian Government, IP Australia in corresponding Australian Patent Application No. 2021266317. (3 pages).
[cited by applicant]
Office Action (Patent examination report 4) issued Mar. 3, 2022, by the New Zealand Intellectual Property Office in corresponding New Zealand Patent Application No. 744940. (9 pages).
[cited by applicant]
Office Action (Patent examination report 5) issued Mar. 3, 2022, by the New Zealand Intellectual Property Office in corresponding New Zealand Patent Application No. 744940. (1 page).
[cited by applicant]
Notice of Allowance issued on May 19, 2021, by the U.S. Patent and Trademark Office in U.S. Appl. No. 16/074,981. (7 pages).
[cited by applicant]
Clayden et al. “Organic Chemistry,” Oxford University Press, 2012, 2nd Edition. (1,469 pages).
[cited by applicant]
Wang et al., “Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer,” AAPS Advances in the Pharmaceutical Science Series, vol. 17, Springer International Publishing, 2015. (248 pages).
[cited by applicant]
Wuytswinkel et al., “A convergent synthesis of heterocyclic dendrimers using the 1,3-dipolar cycloaddition reaction of organic azides and acetylenedicarboxylate esters,” Journal of the Chemical Society, Perkin Transacti…
[cited by applicant]
Office Action issued on Jun. 28, 2021, by the Canadian Patent Office in corresponding Canadian Patent Application No. 3,013,412. (5 pages).
[cited by applicant]
Examination Report issued on May 31, 2021, by the Indian Patent Office in corresponding Indian Patent Application No. 201817029224 and an English translation of the Report. (8 pages).
[cited by applicant]
Substantive Examination Adverse Report issued on Aug. 13, 2021, by the Intellectual Property Corporation of Malaysia in corresponding Malaysian Patent Application No. PI 2018001395. (2 pages).
[cited by applicant]
Patent examination report 1 issued on Mar. 3, 2021, by the New Zealand Intellectual Property Office in corresponding New Zealand Patent Application No. 744940. (10 pages).
[cited by applicant]
Patent examination report 2 issued on Sep. 16, 2021, by the New Zealand Intellectual Property Office in corresponding New Zealand Patent Application No. 744940. (10 pages).
[cited by applicant]
Substantive Examination Report issued Oct. 15, 2020, by the Intellectual Property Office of the Philippines Bureau of Patents in corresponding Philippine Patent Application No. 1/2018/501638. (5 pages).
[cited by applicant]
Examination Review Report issued on Mar. 23, 2021, by the Intellectual Property Office of Singapore in corresponding Singaporean Patent Application No. 11201806594Q. (5 pages).
[cited by applicant]
Written Opinion issued on Nov. 11, 2019, by the Intellectual Property Office of Singapore in corresponding Singaporean Patent Application No. 11201806594Q. (8 pages).
[cited by applicant]
Notice of Acceptance for Patent Application issued on Aug. 31, 2021, by the Australian Patent Office in corresponding Australian Patent Application No. 2016202632. (3 pages).
[cited by applicant]
Communication pursuant to Article 94(3) EPC issued Dec. 12, 2021, by the European Patent Office in corresponding European Patent Application No. 16715987.0. (5 pages).
[cited by applicant]
Notice of Grant for Patent issued on Dec. 23, 2021, by the Australian Patent Office in corresponding Australian Patent No. 2016202632. (1 page).
[cited by applicant]
Notice of Grant for Patent issued on Jan. 25, 2024, by the Australian Patent Office in corresponding AU Patent No. 2021266317 (1 pages).
[cited by applicant]
Office Action (Examination Report) issued on Aug. 26, 2024, by the Australian Patent Office in corresponding AU Application No. 2023248079 (4 pages).
[cited by applicant]
Office Action issued on Sep. 13, 2024, by the U.S. Patent and Trademark Office in related U.S. Appl. No. 17/373,950 (15 pages).
[cited by applicant]
Lutz, “The Configurations of the Unsaturated Dibromo 1,4-Diketones and Ketonic Acids. Synthesis and Structure of CIS and Trans Beta-Benzoyldibromo-Acrylic Acids and Some of Their Derivatives. Studies on Unsaturated 1,4-…
[cited by applicant]
Examination Report No. 1 issued on Aug. 31, 2020, by the Australian Patent Office in corresponding Australian Patent Application No. 2016202632. (5 pages).
[cited by applicant]
International Preliminary Report on Patentability issued on Oct. 11, 2018 by the State Intellectual Property Office of the People's Republic of China in corresponding International Patent Application No. PCT/IB2016/0505…
[cited by applicant]
Office Action issued on Feb. 24, 2021, by the U.S. Patent and Trademark Office in U.S. Appl. No. 16/074,981. (11 pages).
[cited by applicant]
Written Opinion (PCT/ISA/237) mailed on Oct. 21, 2016, by the State Intellectual Property Office of the P.R. China as the International Searching Authority for International Application No. PCT/IB2016/050580.
[cited by applicant]
Office Action issued on Apr. 14, 2020, by the Canadian Patent Office in corresponding Canadian Patent Application No. 3,013,412. (5 pages).
[cited by applicant]
Office Action issued on Nov. 10, 2020, by the Canadian Patent Office in corresponding Canadian Patent Application No. 3,013,412. (4 pages).
[cited by applicant]
Extended European search report issued on Aug. 7, 2019, by the European Patent Office in corresponding European Patent Application No. 16715987.0. (6 pages).
[cited by applicant]
International Search Report (PCT/ISA/210) mailed on Oct. 21, 2016, by the State Intellectual Property Office of the P.R. China as the International Searching Authority for International Application No. PCT/IB2016/050580.
[cited by applicant]
Zitzmann et al., “Arginine-Glycine-Aspartic Acid (RGD)-Peptide Binds to Both Tumor and Tumor-Endothelial Cells in Vivo,” Cancer Research, (Sep. 15, 2002), vol. 62, pp. 5139-5143.
[cited by applicant]
Adams et al., “Generating improved single-chain Fv molecules for tumor targeting,” Journal of Immunological Methods (1999), vol. 231, pp. 249-260.
[cited by applicant]
Adem et al., “Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload,” Bioconjugate Chemistry, (2014), vol. 25, No. 4, pp. 656-664.
[cited by applicant]
Afar et al., “Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer,” Molecular Cancer Therapeutics, (2004), vol. 3, No. 8, pp. 921-932.
[cited by applicant]
Albelda et al., “Integrin Distribution in Malignant Melanoma: Association of the β3 Subunit with Tumor Progression,” Cancer Research, (Oct. 15, 1990), vol. 50, No. 20, pp. 6757-6764.
[cited by applicant]
Almagro et al., “Humanization of antibodies,” Frontiers in Bioscience, (Jan. 1, 2008), vol. 13, pp. 1619-1633.
[cited by applicant]
Almutairi et al., “Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis,” Proceedings of the National Academy of Sciences, (Jan. 20, 2009), vol. 106, No. 3, pp. 685-690.
[cited by applicant]
Anderl et al., “Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology,” Beilstein Journal of Organic Chemistry, (2012), vol. 8, pp. 2072-2084.
[cited by applicant]
Anderson et al., “A Solid-Phase Approach to the Phallotoxins: Total Synthesis of [Ala7]-Phalloidin,” Journal of Organic Chemistry, (2005), vol. 70, pp. 4578-4584.
[cited by applicant]
Arrillaga-Romany et al., “Current status of antiangiogenic therapies for glioblastomas,” Expert Opinion on Investigational Drugs, (2014), vol. 23, No. 2, pp. 199-210.
[cited by applicant]
Axup et al., “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids,” Proceedings of the National Academy of Sciences, (Oct. 2, 2012), vol. 109, No. 40, pp. 16101-16106.
[cited by applicant]
Badescu et al., “Bridging Disulfides for Stable and Defined Antibody Drug Conjugates,” Bioconjugate Chemistry, (2014), vol. 25, No. 6, pp. 1124-1136.
[cited by applicant]
Balasubramanian et al., “Total Synthesis and Biological Evaluation of Tubulysin U, Tubulysin V, and Their Analogues,” Journal of Medicinal Chemistry, (2009), vol. 52, No. 2, pp. 238-240.
[cited by applicant]
Barak et al., “Differential staining of actin in metaphase spindles with 7-nitrobenz-2-oxa-1,3-diazole-phallacidin and fluorescent DNase: Is actin involved in chromosomal movement?,” Proceedings of the National Academy …
[cited by applicant]
Barbanti-Brodano et al., “Selective Killing of Macrophages by Amanitin-Albumin Conjugates,” Nature New Biology, (Jun. 27, 1973), vol. 243, pp. 281-283.
[cited by applicant]
Bartlett et al., “Stereoselective Synthesis of the Dihydroxyisoleucine Constituent of the Amanita Mushroom Toxins,” Tetrahedron Letters, (1982), vol. 23, No. 6., pp. 619-622.
[cited by applicant]
Batori et al., “Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain,” Protein Engineering, (2002), vol. 15, No. 12, pp. 1015-1020.
[cited by applicant]
Baumann et al., “Identification of Structural Features Involved in Binding of α-Amanitin to a Monoclonal Antibody,” Biochemistry, (1993), vol. 32, No. 15, pp. 4043-4050.
[cited by applicant]
Bermbach et al., “Epidermal Growth Factor Labeled β-Amanitin-Poly-L-ornithine: Preparation and Evidence for a Specific Cytotoxicity,” (1990), vol. 29, pp. 6839-6845.
[cited by applicant]
Beste et al., “Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold,” Proceedings of the National Academy of Sciences, vol. 96, No. 5, pp. 1898-1903.
[cited by applicant]
Birker-Robaczewska et al., “The Expression of Urotensin II Receptor (U2R) is Up-regulated by Interferon-γ,” Journal of Receptors and Signal Transduction, (2003), vol. 23, No. 4, pp. 289-305.
[cited by applicant]
Boccon-Gibod et al., “An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer,” Therapeutic Advances in Urology, (2011), vol. 3, No. 3, pp. 127-140.
[cited by applicant]
Boersma et al., “Bispecific Designed Ankyrin Request Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling,” The Journal of Biological Chemistry, (Dec. 2, 2…
[cited by applicant]
Boersma et al., “DARPins and other repeat protein scaffolds: advances in engineering and applications,” Current Opinion in Biotechnology, (2011), vol. 22, pp. 849-857.
[cited by applicant]
Boger et al., “Parallel Synthesis and Evaluation of 132 (+)-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) Analogues of CC-1065 and the Duocarmycins Defining the Contribution of the DNA-Binding Domain,” Journa…
[cited by applicant]
Bonetti et al., “Increased Penetration of Amanitine into Hepatocytes when Conjugated with Albumin,” Archives of Toxicology, (1976) vol. 35, pp. 69-73.
[cited by applicant]
Botos et al., “The Structural Biology of Toll-like Receptors,” Structure, (Apr. 13, 2011), vol. 19, pp. 447-459.
[cited by applicant]
Bouvier et al., “Leishmanolysin: Surface Metalloproteinase of Leishmania,” Methods in Enzymology, (1995), vol. 248, pp. 614-633.
[cited by applicant]
Boylan et al., “Conjugation Site Heterogeneity Causes Variable Electrostatic Properties in Fc Conjugates,” Bioconjugate Chemistry, (2013), vol. 24, pp. 1008-1016.
[cited by applicant]
Brannigan et al., “Protein engineering 20 years on,” Nature Reviews: Molecular Cell Biology, (Dec. 2002), vol. 3, pp. 964-970.
[cited by applicant]
Brich et al., “Preparation and characterization of a water soluble dextran immunoconjugate of doxorubicin and the monoclonal antibody (ABL 364),” Journal of Controlled Release, (1992), vol. 19, pp. 245-258.
[cited by applicant]
Brodner et al., “Identification of the Amatoxin-Binding Subunit of RNA Polymersa B by Affinity Labeling Experiments. Subunit B 3—the True Amatoxin Receptor Protein of Multiple RNA Polymerase B,” Biochemistry, (1976), vo…
[cited by applicant]
Brueckner et al., “Structural basis of transcription inhibition by α-amanitin and implications for RNA polymerase II translocation,” Nature Structural & Molecular Biology, (Aug. 2008), vol. 15, No. 8, pp. 811-818.
[cited by applicant]
Burg et al., “NG2 Proteoglycan-binding Peptides Target Tumor Neovasculature,” Cancer Research, (Jun. 15, 1999), vol. 59, pp. 2869-2874.
[cited by applicant]
Burgess et al., “The complex mediators of cell growth and differentiation,” Immunology Today, (Jun. 1984), vol. 5, No. 6, pp. 155-158.
[cited by applicant]
Camacho, Luis H., “CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations,” Cancer Medicine, (2015), vol. 4, No. 5, pp. 661-672.
[cited by applicant]
Chafin et al., “Action of α-Amanitin during Pyrophosphorolysis and Elongation by RNA Polymerase II,” The Journal of Biological Chemistry, (Aug. 11, 1995), vol. 270, No. 32, pp. 19114-19119.
[cited by applicant]
Chai et al., “Discovery of 23 Natural Tubulysins from Angiococcus disciformis An d48 and Cystobacter SBCb004,” Chemistry & Biology, (Mar. 26, 2010), vol. 17, pp. 296-309.
[cited by applicant]
Chandrasekhar et al., “Toward Tubulysin: Gram-Scale Synthesis of Tubuvaline-Tubuphenylalanine Fragment,” Journal of Organic Chemistry, (2009), vol. 74, pp. 9531-9534.
[cited by applicant]
Chari et al., “Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy,” Angewandte Chemie International Edition, (2014), vol. 53, pp. 3796-3827.
[cited by applicant]
Chari et al., “Targeted Cancer Therapy: Conferring Specificity to Cytotxic Drugs,” Accounts of Chemical Research, (Jan. 2008), vol. 41, No. 1, pp. 98-107.
[cited by applicant]
Chen et al., “Integrin Targeted Delivery of Chemotherapeutics,” Theranostics, (2011), vol. 1, pp. 189-200.
[cited by applicant]
Chen et al., “Synthesis of Doxorubicin Conjugates Through Hydrazone Bonds to Melanotransferrin P97,” Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, (2003), vol…
[cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries,” Letters to Nature, (Aug. 15, 1991), vol. 352, pp. 624-628.
[cited by applicant]
Cochlovius et al., “Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 × CD19 Tandem Diabody, and CD28 Costimulation,” Cancer Research, (Aug. 15, 2000), vol. 60,pp. 4336-4341.
[cited by applicant]
Davis et al., “A Conjugate of α-Amanitin and Monoclonal Immunoglobulin G to Thy 1.2 Antigen is Selectively Toxic to T Lymphoma Cells,” Science, (Sep. 18, 1981), vol. 213, pp. 1385-1388.
[cited by applicant]
De Lamo Marin et al., “A Practical and Efficient Total Synthesis of Potent Insulinotropic (2S,3R,4S)-4-Hydroxyisoleucine through a Chiral N-Protected γ-Keto-α-aminoester,” European Journal of Organic Chemistry, (2010), …
[cited by applicant]
Debruyne et al., “Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer,” Future Oncology, (2006), vol. 2, No. 6, pp. 677-696.
[cited by applicant]
Dechantsrelter et al., “N-Methylated Cyclic RGD Peptides as Highly Active and Selective aVβ3 Integrin Antagonists,” Journal of Medicinal Chemistry, (1999), vol. 42, No. 16, pp. 3033-3040.
[cited by applicant]
Dennler et al., “Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody-Drug Conjugates,” Bioconjugate Chemistry, (2014), vol. 25, pp. 569-578.
[cited by applicant]
Dente et al., “Monoclonal antibodies that recognise filamentous phage: tools for phage display technology,” Gene (Oct. 11, 1994), vol. 148, No. 1, pp. 7-13.
[cited by applicant]
Dhar et al., “Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles,” Proceedings of the National Academy of Sciences, (Nov. 11, 2008), vol. 105, No. 45,…
[cited by applicant]
Dillman, Robert O., “Cancer Immunotherapy,” Cancer Biotherapy and Radiopharmaceuticals, (2011), vol. 26, No. 1. (64 pages).
[cited by applicant]
Dömling et al., “Total Synthesis of Tubulysin U and V,” Angewandte Chemie International Edition, (2006), vol. 45, pp. 7235-7239.
[cited by applicant]
Drake et al., “Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes,” Bioconjugate Chemistry, …
[cited by applicant]
Dudek et al., “First Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer,” Clinical Cancer Research, (Dec. 1, 2007), vol. 13, …
[cited by applicant]
Dunn et al., “Subsite Preferences of Retroviral Proteinases,” Methods in Enzymology, (1994), vol. 241. (33 pages).
[cited by applicant]
Edelman et al., “The Covalent Structure of an Entire γG Immunoglobulin Molecule,” (May 1969), vol. 63, No. 1, pp. 78-85.
[cited by applicant]
Epelbaum et al., “Molecular and Pharmacological Characterization of Somatostatin Receptor Subtypes in Adrenal, Extraadrenal, and Malignant Pheochromocytomas,” Journal of Clinical Endocrinology and Metabolism, (Jun. 1995…
[cited by applicant]
Epenetos et al., “Limitations of Radiolabeled Monoclonal Antibodies for Localization of Human Neoplasms,” Cancer Research, (Jun. 1986), vol. 46, pp. 3183-3191.
[cited by applicant]
Faulstich et al., “Ether Derivatives of α-Amanitin. Introduction of Spacer Moieties, Lipophilic Residues, and Radioactive Labels,” Biochemistry, (1981), vol. 20, pp. 6498-6504.
[cited by applicant]
Faulstich et al., “Protein Conjugates of Fungal Toxins,” Methods in Enzymology, (1985), vol. 112, pp. 225-237.
[cited by applicant]
Fekete et al., “Receptors for Luteinizing Hormone-Releasing Hormone, Somatostatin, Prolactin, and Epidermal Growth Factor in Rat and Human Prostate Cancers and in Benign Prostate Hyperplasia,” The Prostate, (1989), vol.…
[cited by applicant]
Ferris et al., “Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape,” Journal of Clinical Oncology, (Oct. 1, 2010), vol. 28, No. 28, pp. 4390-4399.
[cited by applicant]
Fiume, Luigi, “Penetration of a Beta-Amanitin/Rabbit-Albumin Conjugate into Hepatic Parenchymal Cells,” The Lancet, (Oct. 18, 1969), pp. 853-854.
[cited by applicant]
Francis et al., “A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours,” British Journal of Cancer, (2002), vol. 87, pp. 600-60…
[cited by applicant]
Frangione et al., “Disulphide Bridges of Immunoglobin GI Heavy Chains,” Nature, (Dec. 2, 1967), vol. 216, pp. 939-941.
[cited by applicant]
Frangione et al., “Intrachain Disulphide Bridges in Immunoglobulin G Heavy Chains,” Biochemical Journal, (1968), vol. 106, pp. 15-21.
[cited by applicant]
Frangione et al., “Structural Studies of Immunoglobulin G,” Nature, (Jan. 11, 1969), vol. 221, pp. 145-148.
[cited by applicant]
Frangione et al., “Variations in the S—S Bridges of Immunoglobins G: Interchain Disulphide Bridges of γG3 Myeloma Proteins,” Journal of Molecular Biology, (1968), vol. 33, pp. 893-906.
[cited by applicant]
Frankel et al., “Cell Surface Receptor-Targeted Therapy of Acute Myeloid Leukemia: A Review,” Cancer Biotherapy & Radiopharmaceuticals, (2000), vol. 15, No. 5, pp. 459-476.
[cited by applicant]
Friestad et al., “Stereoselective Mn-Mediated Coupling of Functionalized Iodides and Hydrazones: A Synthetic Entry to the Tubulysin γ-Amino Acids,” Organic Letters, (2004), vol. 6, No. 19, pp. 3249-3252.
[cited by applicant]
Friestad et al., “Synthesis of γ-Amino Esters via Mn-Mediated Radical Addition to Chiral γ-Hydrazonoesters,” Organic Letters, (2009), vol. 11, No. 5, pp. 1095-1098.
[cited by applicant]
Fukata et al., “Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders,” Seminars in Immunology, (2009), vol. 21, pp. 242-253.
[cited by applicant]
Garanger et al., “Tumor Targeting with RGD Peptide Ligands-Design of New Molecular Conjugates for Imaging and Therapy of Cancers,” Anti-Cancer Agents in Medicinal Chemistry, (2007), vol. 7, pp. 552-558.
[cited by applicant]
Gerber et al., “Antibody drug-conjugates targeting the tumor vasculature,” mAbs, (May/Jun. 2009), vol. 1, No. 3, pp. 247-253.
[cited by applicant]
Geysen et al., “Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein,” Proceedings of the National Academy of Science…
[cited by applicant]
Ginj et al., “Radiolabeled somatostatin receptor antagonist are preferable to agonists for in vivo peptide receptor targeting of tumors,” Proceedings of the National Academy of Sciences, (Oct. 31, 2016), vol. 103, No. 4…
[cited by applicant]
Gonzalez et al., “Bombesin-Related Peptides and their receptors: recent advances in their role in physiology and disease states,” Current Opinion in Endocrinology, Diabetes and Obesity, (Feb. 2008), vol. 15, No. 1, pp. …
[cited by applicant]
Goodman et al., “Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins,” Journal of Medicinal Chemistry, (2002), vol. 45, pp. 1045-1051.
[cited by applicant]
Gorn et al., “Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction,” The Journal of Clinic…
[cited by applicant]
Guo et al., “Culture conditions and analysis of amanitins on Amanita spissa,” Acta Microbiologica Sinica, (Jun. 4, 2006), vol. 46, No. 3, pp. 373-378.
[cited by applicant]
Hackel et al., “The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold,” Protein Engineering Design & Selection, (2010), vol. …
[cited by applicant]
Hallen et al., “Gene family encoding the major toxins of lethal Amanita mushrooms,” Proceedings of the National Academy of Sciences, (Nov. 27, 2007), vol. 104, No. 48, pp. 19097-19101.
[cited by applicant]
Halmos et al., “High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers,” The Journal of Clinical Endocrinology & …
[cited by applicant]
Halmos et al., “Human Ovarian Cancers Express Somatostatin Receptors,” The Journal of Clinical Endocrinology & Metabolism, (2000), vol. 85, No. 10, pp. 3509-3512.
[cited by applicant]
Hamblett et al., “Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate,” Clinical Cancer Research, (Oct. 15, 2004), vol. 10, pp. 7063-7070.
[cited by applicant]
Harlow et al., “Antibodies: A Laboratory Manual,” Cold Spring Harbor Laboratory, (1988). (742 pages).
[cited by applicant]
Henning et al., “Substance-P Receptors in Human Primary Neoplasms: Tumoral and Vascular Localization,” International Journal of Cancer, (1995), vol. 61, pp. 786-792.
[cited by applicant]
Heyl et al., “Facile Direct Synthesis of Acetylenedicarbonxamides,” Synthesis, (Mar. 17, 2014), vol. 46, No. 11, pp. 1463-1468.
[cited by applicant]
Hillier et al., “Preclinical Evaluation of Novel Glutamate-Urea-Lysin Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer,” Cancer Research, (Sep. 1, 2009), …
[cited by applicant]
Hinman et al., “Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics,” Cancer Research, (Jul. 15, 1993), vol. 53, pp. 3336-3342.
[cited by applicant]
Hofer et al., “Molecularly Defined Antibody Conjugation through a Selenocysteine Interface,” Biochemistry, (2009), vol. 48, pp. 12047-12057.
[cited by applicant]
Holt et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, (Nov. 2003), vol. 21, No. 11, pp. 484-490.
[cited by applicant]
Horgen et al., “The Insensitivity of Mushroom Nuclear RNA Polymerase Activity to Inhibition by Amatoxins,” Archives of Microbiology, vol. 118, No. 3, pp. 317-319.
[cited by applicant]
Hotz et al., “Systemic cancer immunotherapy with Toll-like receptor 7 agonists,” OncoImmunology, (2012), vol. 1, No. 2, pp. 227-228.
[cited by applicant]
Houdebine, Louis-Marie, “Antibody manufacture in transgenic animals and comparisons with other systems,” Current Opinion in Biotechnology, (Dec. 1, 2002), vol. 13, No. 6, pp. 625-629.
[cited by applicant]
Hurwitz et al., “The Covalent Binding of Daunomycin and Adriamycin to Antibodies, with Retention of Both Drug and Antibody Activities,” Cancer Research, (May 1975), vol. 35, pp. 1175-1181.
[cited by applicant]
Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,” Research Article, (Dec. 8, 1989), pp. 1275-1281.
[cited by applicant]
Javier et al., “Aptamer-Targeted Gold Nanoparticles as Molecular-Specific Contrast Agents for Reflectance Imaging,” Bioconjugate Chemistry, (2008), vol. 19, pp. 1309-1312.
[cited by applicant]
Junutula et al., “Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer,” Clinical Cancer Research, (2010), vol. 16, No. 1…
[cited by applicant]
Junutula et al., “Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index,” Nature Biotechnology, (Aug. 2008), vol. 26, No. 8, pp. 925-932.
[cited by applicant]
Karlson-Stiber et al., “Cytotoxic fungi—an overview,” Toxicon, (2003), vol. 42, pp. 339-349.
[cited by applicant]
Kasturi et al., “Programming the magnitude and persistence of antibody responses with innate immunity,” Nature (Feb. 24, 2011), vol. 470, pp. 543-547.
[cited by applicant]
Kim et al., “C-2 Modified Taxol Analogs with Improved Aqueous Solubility,” Bulletin—Korean Chemical Society, (1999), vol. 20, No. 12, pp. 1389-1390.
[cited by applicant]
King et al., “Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates,” Bioconjugate Chemical, (1999), vol. 10, pp. 279-288.
[cited by applicant]
King et al., “Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains,” Journal of Medicinal Chemistry, (2002), vol. 45, pp. 433…
[cited by applicant]
Kiprijanov et al., “Generation and Production of Engineered Antibodies,” Molecular Biotechnology, (Feb. 2004), vol. 26, No. 1, pp. 39-60.
[cited by applicant]
Köhler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, (Aug. 7, 1975), vol. 256, pp. 495-497.
[cited by applicant]
Koide et al., “The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins,” Journal of Molecular Biology, (1998), vol. 284, No. 4, pp. 1141-1151.
[cited by applicant]
Koppan et al., “Targeted Cytotoxic Analog of Luteinizing Hormone-Releasing Hormone AN-207 Inhibits the Growth of PC-82 Human Prostate Cancer in Nude Mice,” The Prostate, (1999), vol. 38, pp. 151-158.
[cited by applicant]
Kouroumalis et al., “Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study,” Gut, (1998), vol. 42, pp. 442-447.
[cited by applicant]
Kratz et al., “Preparation, Characterization and in Vitro Efficacy of Albumin Conjugates of Doxorubicin,” Biological & Pharmaceutical Bulletin, (1998), vol. 21, No. 1, pp. 56-61.
[cited by applicant]
Kratz et al., “Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derviative with Specific Albumin-Binding Propert…
[cited by applicant]
Kubicek et al., “The Tubulin-Bound Structure of the Antimitotic Drug Tubulysin,” Angewandte Chemie International Edition, (2010), vol. 49, pp. 4809-4812.
[cited by applicant]
Laakkonen et al., “Homing peptides as targeted delivery vehicles,” Integrative Biology, (2010), vol. 2, pp. 326-337.
[cited by applicant]
Laguzza et al., “New Antitumor Monoclonal Antibody-Vinca Conjugates LY203725 and Related Compounds: Design, Preparation, and Representative in Vivo Activity,” Journal of Medicinal Chemistry, (1989), vol. 32, pp. 548-555.
[cited by applicant]
Lane, Tim, “BCG immunotherapy for superficial bladder cancer,” Journal of the Royal Society of Medicine, (Jun. 2001), vol. 94, p. 316.
[cited by applicant]
Lau, et al., “A molecular immunology approach to antibody humanization and functional optimization”, Molecular Immunology, vol. 44, 2007, pp. 1986-1998.
[cited by applicant]
Lau et al., “Novel Doxorubicin-Monoclonal Anti-carcinoembryonic Antigen Antibody Immunoconjugate Activity in vitro,” Bioorganic & Medicinal Chemistry, (1995), vol. 3, No. 10, pp. 1305-1312.
[cited by applicant]
Lazar et al., “A molecular immunology approach to antibody humanization and functional optimization,” Molecular Immunology, (2007), vol. 44, pp. 1986-1998.
[cited by applicant]
Lee et al., “Designing dendrimers for biological applications,” Nature Biotechnology, (Dec. 2005), vol. 23, No. 12, pp. 1517-1526.
[cited by applicant]
Lei et al., “Binding of Monoclonal Antibodies against the Carboxyl Terminal Segment of the Nicotinic Receptor o' Subunit Suggests an Unusual Transmembrane Disposition of This Sequence Region,” Biochemistry, (1995), vol.…
[cited by applicant]
Li et al., “Human antibodies for immunotherapy development generated via a human B cell hybridoma technology,” Proceedings of the National Academy of Sciences, (Mar. 7, 2006), vol. 103, No. 10, pp. 3557-3562.
[cited by applicant]
Liong et al., “Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery,” ACS Nano, (2008), vol. 2, No. 5, pp. 889-896.
[cited by applicant]
Litten, Walter, “The Most Poisonous Mushrooms,” Scientific American, Inc., (1975), vol. 232, No. 3, pp. 90-101.
[cited by applicant]
Little et al., “Surface Display of Antibodies,” Biotechnology Advances, (1994), vol. 12, No. 3, pp. 539-555.
[cited by applicant]
Liu et al., “Disulfide bond structures of IgG molecules: Structural variations, chemical modifications and possible impacts to stability and biological function,” mAbs, (Jan./Feb. 2012), vol. 4, No. 1, pp. 17-23.
[cited by applicant]
Liu et al., “Engineering therapeutic monoclonal antibodies,” Immunological Reviews, (2008), vol. 222, pp. 9-27.
[cited by applicant]
Liu et al., “Ranking the Susceptibility of Disulfide Bonds in Human IgG1 Antibodies by Reduction, Differential Alkylation, and LC-MS Analysis,” Analytical Chemistry, (Jun. 15, 2010), vol. 82, No. 12, pp. 5219-5226.
[cited by applicant]
Liu et al., “Targeting Cell Surface Alpha(v)beta(3) Integrin Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin Prodrug,” Molecular Pharmaceutics, (2012), vol. 9, pp. 168-175.
[cited by applicant]
Loh et al., “Somatostatin receptors in nasopharyngeal carcinoma,” Virchows Archiv, (2002), vol. 441, pp. 444-448.
[cited by applicant]
Low et al., “Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases,” Accounts of Chemical Research, (Jan. 2008), vol. 41, No. 1, pp. 120-129.
[cited by applicant]
Lundholm et al., “Plaque Production by the Polyoma Virus,” Letters to the Editors, (1959) pp. 396-397.
[cited by applicant]
Luo et al., “Peptide Macrocyclization Catalyzed by a Prolyl Oligopeptidase Involved in α-Amanitin Biosynthesis,” Chemistry & Biology, (Dec. 18, 2014), vol. 21, pp. 1610-1617.
[cited by applicant]
Lutz et al., “Efficient construction of therapeutics, bioconjugates, biomaterials and bioactive surfaces using azide-alkyne “click” chemistry,” Advanced Drug Delivery Reviews, (2008), vol. 60, pp. 958-970.
[cited by applicant]
Lyon et al., “Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates,” Nature Biotechnology, (2014), vol. 32, pp. 1059-1062.
[cited by applicant]
Maisonneuve et al., “Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants,” Proceedings of the National Academy of Sciences, (Aug. 26, 2014), vol. 111, No. 34, pp. 12294-12299.
[cited by applicant]
Martin-Killias et al., “A Novel Fusion Toxin Derived from an EpCam-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity,” Clinical Cancer Research, (Jan. 1, 2011), vol. 17, No. 1, pp. 100-110.
[cited by applicant]
Matayoshi et al., “Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer,” Science, (1999), vol. 247, No. 4945, pp. 954-958.
[cited by applicant]
May et al., “High Yielding Synthesis of 3α-Hydroxypyrrolo[2,3-b]indoline Dipeptide Methyl Esters: Synthons for Expedient Introduction of the Hydroxypyrroloindoline Moiety into Larger Peptide-Based Natural Products and f…
[cited by applicant]
May et al., “Intraannular Savige-Fontana Reaction: One-Step Conversion of One Class of Monocyclic Peptides into Another Class of Bicyclic Peptides,” Chemistry: A European Journal, (2008), vol. 14, pp. 3404-3409.
[cited by applicant]
May et al., “Synthesis, Characterisation, and In Vitro Evaluation of Pro2-Ile3-S-Deoxo-Amaninamide and Pro2-D-allo-Ile3-S-Deoxo-Amaninamide: Implications for Structure-Activity Relationships in Amanitin Conformation and…
[cited by applicant]
May et al., “Tryptathionine Bridges in Peptide Synthesis,” PeptideScience, (2007), vol. 88, No. 5, pp. 714-724.
[cited by applicant]
Means et al., “Structure and function of Toll-like receptor proteins,” Life Sciences, (2000), vol. 68, pp. 241-258.
[cited by applicant]
Medarova et al., “In vivo imaging of siRNA delivery and silencing in tumors,” Nature Medicine, (Mar. 2007), vol. 13, No. 3, pp. 372-377.
[cited by applicant]
Medina et al., “Targeted Liposomal Drug Delivery in Cancer,” Current Pharmaceutical Design, (2004), vol. 10, pp. 2981-2989.
[cited by applicant]
Mehrling, Thomas, “Chemotherapy is getting ‘smarter,’” Future Oncology, (2015), vol. 11, No. 4, pp. 549-552.
[cited by applicant]
Metzger et al., “Synthesis of Nα-Fmoc protected derivatives of S-(2,3-dihydroxypropyl)-cysteine and their application in peptide synthesis,” International Journal of Peptide and Protein Research, (1991), vol. 38, pp. 54…
[cited by applicant]
Miller et al., “Design, Construction, and In Vitro Analyses of Multivalent Antibodies,” The Journal of Immunology, (2003), vol. 170, pp. 4854-4861.
[cited by applicant]
Miller et al., “Somatostatin binding in normal and malignant human gastrointestinal mucosa,” British Journal of Cancer, (1992), vol. 66, No. 2, pp. 391-395.
[cited by applicant]
Miller et al., “Synthesis of Taxoids with Improved Cytotoxicity and Solubility for Use in Tumor-Specific Delivery,” Journal of Medicinal Chemistry, (2004), vol. 47, pp. 4802-4805.
[cited by applicant]
Milstein, C., “The Disulphide Bridges of Immunoglobulin x-Chains,” Biochemical Journal, (1966), vol. 101, pp. 338-351.
[cited by applicant]
Moertel et al., “Expression of Somatostatin Receptors in Childhood Neuroblastoma,” American Journal of Clinical Pathology: Anatomic Pathology, (Dec. 1, 1994), vol. 102, No. 6, pp. 752-756.
[cited by applicant]
Mohammad et al., “A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model,” International Journal of Oncology, (1999), vol. 15, pp. 367-…
[cited by applicant]
Moldenhauer et al., “Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma,” Journal of the National Cancer Institute, (Apr. 18, 2012), vol.…
[cited by applicant]
Moore et al., “Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma,” Blood, (Apr. 28, 2011), vol. 117, No. 17, pp. 4542-4551.
[cited by applicant]
Moshnikova et al., “A˜ntiproliferative Effect of pHLIP-Amanitin,” Biochemistry, (2013), vol. 52, pp. 1171-1178.
[cited by applicant]
Moyse et al., “Somatostatin Receptors in Human Growth Hormone and Prolactin-Secreting Pituitary Adenomas,” Journal of Clinical Endocrinology and Metabolism, (1985), vol. 61, No. 1, pp. 98-103.
[cited by applicant]
Mullard, Asher, “Maturing antibody-drug conjugate pipeline hits 30,” Nature Reviews, (May 2013), vol. 12, pp. 329-332.
[cited by applicant]
Mullersman et al., “Conjugation of N-acylated amino sugars to protein by reductive alkylation using sodium cyanoborohydride: application to an azo derivative of α-amanitin,” Biochemistry and Cell Biology, (1991), vol. 6…
[cited by applicant]
Mullersman et al., “Periodate oxidation products derived from methylated α-amanitin: evidence for distinct aldehydic and non-aldehydic forms,” International Journal of Peptide and Protein Research, (1991), vol. 38, pp. …
[cited by applicant]
Muraoka et al., “Effective Production of Amanitins by Two-Step Cultivation of the Basidiomycete, Galerina fasciculata GF-060,” Journal of Bioscience and Bioengineering, (2000), vol. 89, No. 1, pp. 73-76.
[cited by applicant]
Muyldermans et al., “Nanobodies: Natural Single-Domain Antibodies,” The Annual Review of Biochemistry, (2013), vol. 82, pp. 775-797.
[cited by applicant]
Nakase et al., “Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo,” Journal of Controlled Release, (2012), vol. 159, pp. 181-188.
[cited by applicant]
Neri et al., “Interfering with pH regulation in tumours as a therapeutic strategy,” Nature Reviews, (Oct. 2011), vol. 10, pp. 767-777.
[cited by applicant]
Nicolaou et al., “Calicheamicin θ1 I: A Rationally Designed Molecule with Extremely Potent and Selective DNA Cleaving Properties and Apoptosis Inducing Activity,” Angewandte Chemie International Edition, (1994), vol. 33…
[cited by applicant]
Nicolaou et al., “Chemical Synthesis and Biological Evaluation of C-2 Taxoids,” Journal of the American Chemical Society, (1995), vol. 117, pp. 2409-2420.
[cited by applicant]
Nicolaou et al., “Chemistry and biology of natural and designed enediynes,” Proceedings of the National Academy of Sciences, (Jul. 1993), vol. 90, pp. 5881-5888.
[cited by applicant]
Nicolaou et al., “Designed Enediynes: A New Class of DNA-Cleaving Molecules with Potent and Selective Anticancer Activity,” Science, (May 22, 1992), vol. 256, pp. 1172-1178.
[cited by applicant]
Niman et al., “Generation of protein-reactive antibodies by short peptides is an event of high frequency: Implications for the structural basis of immune recognition,” Proceedings of the National Academy of Sciences, (A…
[cited by applicant]
Novellino et al., “A listing of human tumor antigens recognized by T cells: Mar. 2004 update,” Cancer Immunology Immunotherapy, (2005), vol. 54, pp. 187-207.
[cited by applicant]
Ohlsson et al., “The Effect of Bombesin, Cholecystokinin, Gastrin, and Their Antagonists on Proliferation of Pancreatic Cancer Cell Lines,” Scandinavian Journal of Gastroenterology, (1999), vol. 34, No. 12, pp. 1224-122…
[cited by applicant]
Ojima et al., “A common pharmacophore for cytotoxic natural products that stabilize microtubules,” Proceedings of the National Academy of Sciences, (Apr. 1999), vol. 96, pp. 4256-4261.
[cited by applicant]
Ojima et al., “Syntheses and Structure—Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity against Drug-Resistant Cancer Cells,” Journal of Medicinal Chemistry, (1996), vol. 39, pp. 3…
[cited by applicant]
Ojima et al., “Syntheses and Structure-Activity Relationships of Taxoids Derived from 14β-Hydroxy-10-deacetylbaccatin III,” Journal of Medicinal Chemistry, (1997), vol. 40, pp. 267-278.
[cited by applicant]
Ojima et al., “Tumor-Specific Novel Taxoid-Monoclonal Antibody Conjugates,” Journal of Medicinal Chemistry, (2002), vol. 45, pp. 5620-5623.
[cited by applicant]
O'Keefe et al., “Characterization of a Transferrin-Diphtheria Toxin Conjugate,” The Journal of Biological Chemistry, (Jan. 25, 1985), vol. 260, No. 2, pp. 932-937.
[cited by applicant]
Okeley et al., “Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody-Drug Conjugation,” Bioconjugate Chemistry, (2013), vol. 24, pp. 1650-1655.
[cited by applicant]
Pando et al., “First Total Synthesis of Tubulysin B,” Organic Letters, (2009), vol. 11, No. 24, pp. 5567-5569.
[cited by applicant]
Pando et al., “The Multiple Multicomponent Approach to Natural Product Mimics: Tubugis, N-Substituted Anticancer Peptides with Picomolar Activity,” Journal of the American Chemical Society, (2011), vol. 133, pp. 7692-76…
[cited by applicant]
Panowski et al., “Site-specific antibody drug conjugates for cancer therapy,” mAbs, (Jan./Feb. 2014), vol. 6, No. 1, pp. 34-45.
[cited by applicant]
Parham, P., “One the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice,” The Journal of Immunology, (Dec. 1983), vol. 131, No. 6, pp. 2895-2902.
[cited by applicant]
Patterson et al., “Expedient Synthesis of N-Methyl Tubulysin Analogues with High Cytotoxicity,” Journal of Organic Chemistry, (2008), vol. 73, pp. 4362-4369.
[cited by applicant]
Peltier et al., “The Total Synthesis of Tubulysin D,” Journal of the American Chemical Society, (2006), vol. 128, pp. 16018-16019.
[cited by applicant]
Pietersz et al., “Immunochemotherapy of a Murine Thymoma with the Use of Idarubicin Monoclonal Antibody Conjugates,” Cancer Research, (Feb. 15, 1988), vol. 48, pp. 926-931.
[cited by applicant]
Pink et al., “Disulphide Bridges of a Human Immunoglobulin G Protein,” Nature, (Dec. 2, 1967), vol. 216, pp. 941-942.
[cited by applicant]
Pink et al., “Inter Heavy-Light Chain Disulphide Bridge in Immune Globulins,” Nature, (Apr. 1, 1967), vol. 214, pp. 92-94.
[cited by applicant]
Porkka et al., “A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo,” Proceedings of the National Academy of Sciences, (May 28, 2002), vol. 99, No. 11, pp. 7444-7449.
[cited by applicant]
Pousse et al., “Brønsted Acid Catalyzed Asymmetric Aldol Reaction: A Complementary Approach to Enamine Catalysis,” Organic Letters, (2010), vol. 12, No. 16, pp. 3582-3585.
[cited by applicant]
Preston et al., “Preparation and Characterization of an aα-Amanitin Azo Derivative with a Free Carboxyl Group and Its Bovine Serum Albumin Conjugate,” Archives of Biochemistry and Biophysics, (Jun. 1981), vol. 209, No. …
[cited by applicant]
Prevost et al., “Somatostatin-14 Mainly Binds the Somatostatin Receptor Subtype 2 in Human Neuroblastoma Tumors,” Neuroendocrinology, (1996), vol. 63, pp. 188-197.
[cited by applicant]
Rabuka et al., “Site-specific chemical protein conjugation using genetically encoded aldehyde tags,” Nature Protocols, (2012), vol. 7, No. 6, pp. 1052-1067.
[cited by applicant]
Raghavan et al., “Cytotoxic Simplified Tubulysin Analogues,” Journal of Medicinal Chemistry, (2008), vol. 51, pp. 1530-1533.
[cited by applicant]
Reddy et al., “In Vivo Structural Activity and Optimization Studies of Folate-Tubulysin Conjugates,” Molecular Pharmaceutics, (2009), vol. 6, No. 5, pp. 1518-1525.
[cited by applicant]
Reubi et al., “Detection of Somatostatin Receptors in Surgical and Percutaneous Needle Biopsy Samples of Carcinoids and Islet Cell Carcinomas,” Cancer Research, (Sep. 15, 1990), vol. 50, pp. 5969-5977.
[cited by applicant]
Reubi et al., “High Density of Somatostatin Receptors in Pituitary Tumors from Acromegalic Patients,” Journal of Clinical Endocrinology and Metabolism, (1984), vol. 59, No. 6, pp. 1148-1151.
[cited by applicant]
Reubi et al., “Hormone-Producing Gastrointestinal Tumors Contain a High Density of Somatostatin Receptors,” Journal of Endocrinology and Metabolism, (1987), vol. 65, No. 6, pp. 1127-1134.
[cited by applicant]
Reubi et al., “In Vitro and In Vivo Detection of Somatostatin Receptors in Human Malignant Lymphomas,” International Journal of Cancer, (1992), vol. 50, pp. 895-900.
[cited by applicant]
Reubi et al., “In Vitro and in Vivo Detection of Somatostatin Receptors in Pheochromocytomas and Paragangliomas,” Journal of Clinical Endocrinology and Metabolism, (1992), vol. 74, No. 5, pp. 1082-1089.
[cited by applicant]
Reubi et al., “Receptor Autoradiographic Evaluation of Cholecystokinin, Neurotensin, Somatostatin and Vasoactive Intestinal Peptide Receptors in Gastro-Intestinal Adenocarcinoma Samples: Where Are They Really Located?” …
[cited by applicant]
Reubi et al., “Regulatory peptide receptors in human hepatocellular carcinomas,” Gut, (1999), vol. 45 pp. 766-774.
[cited by applicant]
Reubi et al., “Somatostatin Receptor Incidence and Distribution in Breast Cancer Using Receptor Autoradiography: Relationship to EGF Receptors,” International Journal of Cancer, (1990), vol. 46, pp. 416-420.
[cited by applicant]
Reubi et al., “Somatostatin Receptors in Differentiated Ovarian Tumors,” American Journal of Pathology, (May 1991), vol. 138, No. 5, pp. 1267-1272.
[cited by applicant]
Reubi et al., “Somatostatin Receptors in Human Prostate and Prostate Cancer,” Journal of Clinical Endocrinology and Metabolism, (1995), vol. 80, No. 9, pp. 2806-2814.
[cited by applicant]
Reubi et al., “Somatostatin Receptors in Human Renal Cell Carcinomas,” Cancer Research, (Nov. 1, 1992), vol. 52, pp. 6074-6078.
[cited by applicant]
Reubi et al., “Visualization of Somatostatin Receptors and Correlation with Immunoreactive Growth Hormone and Prolactin in Human Pituitary Adenomas: Evidence for Different Tumor Subclasses,” Journal of Clinical Endocrin…
[cited by applicant]
Ruoslahti et al., “Anchorage Dependence, Integrins, and Apoptosis,” Cell, (May 20, 1994), vol. 77, pp. 477-478.
[cited by applicant]
Sagman et al., “Indentification of Somatostatin Receptors in Human Small Cell Lung Carcinoma,” Cancer, (Nov. 15, 1990), vol. 66, No. 10, pp. 2129-2133.
[cited by applicant]
Sani et al., “Total Synthesis of Tubulysins U and V,” Angewandte Chemie International Edition, (2007), vol. 46, pp. 3526-3529.
[cited by applicant]
Savige et al., “New Method of Linking Tryptophan to Cysteine Sulphydryle Groups in Peptides and Proteins,” Journal of the Chemical Society, Chemical Communications, (1976), No. 15, pp. 600-601.
[cited by applicant]
Schally et al., “Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors,” European Journal of Endocrinology, (1999), vol. 141, pp. 1-14.
[cited by applicant]
Schmitt et al., “Conformation of Different S-Deoxo-Xaa3-amaninamide Analogues in DMSO Solution as Determined by NMR Spectroscopy. Strong CD Effects Induced by βI, βII Conformation Change,” Journal of the American Chemic…
[cited by applicant]
Schumacher et al., “Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging,” Organic & Biomolecular Chemistry, (2014), vol. 12, pp. 7261-7269.
[cited by applicant]
Scott et al., “Synthesis of Reagents for the One Step Incorporation of Hydrazide Functionality onto the Lysine Residues of Proteins, and Their Use as Linkers for Carbonyl Containing Molecules,” Bioorganic & Medicinal Ch…
[cited by applicant]
Seidah et al., “Pro-Protein Convertases of Subtilisin/Kexin Family,” Methods in Enzymology, (1994), vol. 244, pp. 175-188.
[cited by applicant]
Shen et al., “Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates,” Nature Biotechnology, (Feb. 2012), vol. 30, No. 2, pp. 184-189.
[cited by applicant]
Sievers et al., “Antibody-Drug Conjugates in Cancer Therapy,” The Annual Review of Medicine, (2013), vol. 64, pp. 15-29.
[cited by applicant]
Silverman et al., “Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains,” Nature Biotechnology, (Dec. 2005), vol. 23, No. 12, pp. 1556-1561.
[cited by applicant]
Skerra, Arne, “Alternative binding proteins: Anticalins—harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities,” The FEBS Journal, (2008), vol. 275, pp. 2677-2683.
[cited by applicant]
Skerra, Arne, “Alternative non-antibody scaffolds for molecular recognition,” Current Opinion in Biotechnology, (2007), vol. 18, pp. 295-304.
[cited by applicant]
Skerre, Arne, “Lipocalins as a scaffold,” Biochimica et Biophysica Acta (BBA)—Protein Structure and Molecular Enzymology, (2000), vol. 1482, pp. 337-350.
[cited by applicant]
Sletten et al., “From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions,” Accounts of Chemical Research, (2011), vol. 44, No. 9, pp. 666-676.
[cited by applicant]
Smith et al., “Purification and Kinetic Characterization of Human Cytomegalovirus Assemblin,” Methods in Enzymology, (1994), vol. 244, pp. 412-423.
[cited by applicant]
Smith et al., “The Enediyne Antibiotics,” Journal of Medicinal Chemistry, (May 24, 1996), vol. 39, No. 11, pp. 2103-2117.
[cited by applicant]
Spiegelberg et al., “Human Myeloma IgG Half-Molecules. Structural and Antigenic Analyses,” Biochemistry, (1975), vol. 14, No. 10, pp. 2157-2163.
[cited by applicant]
Srkalovic et al., “Evaluation of Receptors for Somatostatin in Various Tumors Using Different Analogs,” Journal of Clinical Endocrinology and Metabolism, (1990), vol. 70, No. 3, pp. 661-669.
[cited by applicant]
Strop et al., “Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates,” Chemistry & Biology, (Feb. 21, 2013), vol. 20, pp. 161-167.
[cited by applicant]
Strop, Pavel, “Versatility of Microbial Transglutaminase,” Bioconjugate Chemistry, (2014), vol. 25, pp. 855-862.
[cited by applicant]
Temming et al., “RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature,” Drug Resistance Updates, (2005), vol. 8, pp. 381-402.
[cited by applicant]
Thornberry, Nancy, “Interleukin-1β Converting Enzyme,” Methods in Enzymology, (1994), vol. 244, pp. 615-631.
[cited by applicant]
Thumshirn et al., “Multimeric Cyclic RGD Peptides as Potential Tools for Tumor Targeting: Solid-Phase Peptide Synthesis and Chemoselective Oxime Ligation,” Chemistry: A European Journal, (2003), vol. 9, pp. 2717-2725.
[cited by applicant]
Thundimadathil, Jyothi, “Cancer Treatment Using Peptides: Current Therapies and Future Prospects,” Journal of Amino Acids, (2012), vol. 2012. (14 pages).
[cited by applicant]
Tian et al., “A general approach to site-specific antibody drug conjugates,” Proceedings of the National Academy of Sciences, (Feb. 4, 2014), vol. 111, No. 5, pp. 1766-1771.
[cited by applicant]
Tolcher et al., “Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin,” Clinical Cancer Research, (Jan. 2011), vol. 17, No. 2, pp. 363…
[cited by applicant]
Trail et al., “Effect of Linker Variation on the Stability, Potency, and Efficacy of Carcinoma—reactive BR64-Doxorubicin Immunoconjugates,” Cancer Research, (Jan. 1, 1997), vol. 57, pp. 100-105.
[cited by applicant]
Trouet et al., “A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: In vitro and in vivo studies,…
[cited by applicant]
Tumey et al., “Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy,” Bioconjugate Chemistry, (2014), vol. 25, pp. 1871-1880.
[cited by applicant]
Ullrich et al., “Pretubulysin, a Potent and Chemically Accessible Tubulysin Precursor from Angiococcus disciformis,” Angewandte Chemie International Edition, (2009), vol. 48, pp. 4422-4425.
[cited by applicant]
Van Den Mooter, et al., “Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer,” Expert Opinion on Biological Therapy, (2015), vol. 15, No. 5, pp. 749-760.
[cited by applicant]
Van Wuytswinkel et al., “A convergent synthesis of heterocyclic dendrimers using the 1,3-dipolar cycloaddition reaction of organic azides and acetylenedicarboxylate esters,” Journal of the Chemical Society, Perkin Trans…
[cited by applicant]
Villaruz et al., “Immunotherapy in lung cancer,” Translational Lung Cancer Research, (2014), vol. 3, No. 1, pp. 2-14.
[cited by applicant]
Wakankar et al., “Analytical methods for physicochemical characterization of antibody drug conjugates,” mAbs, (Mar./Apr. 2011, vol. 3, No. 2, pp. 161-172.
[cited by applicant]
Wang et al., “A Practical Synthesis of (2S,3R,4S)-4-Hydroxyisoleucine, A Potent Insulinotropic α-Amino Acid from Fenugreek,” European Journal of Organic Chemistry, (2002), vol. 2002, No. 5, pp. 834-839.
[cited by applicant]
Wang et al., “Structural characterization on the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry,” Protein Science, (2005), vol. 14, pp. 2436-2446.
[cited by applicant]
Warpehoski et al., “Stereoelectronic Factors Influencing the Biological Activity and DNA Interaction of Synthetic Antitumor Agents Modeled on CC-1065,” Journal of Medicinal Chemistry, (1988), vol. 31, pp. 590-603.
[cited by applicant]
Weber et al., “Adenovirus Endopeptidases,” Methods in Enzymology, (1994), vol. 244, pp. 595-604.
[cited by applicant]
Weber, Christian H., “Regulation and signaling of human bombesin receptors and their biological effects,” Current Opinion in Endocrinology, Diabetes & Obesity, (2009), vol. 16, pp. 66-71.
[cited by applicant]
Wieland et al., “The Effect of the Chemical Nature of the Side Chains of Amatoxins in the Inhibition of Eukaryotic RNA Polymerase B,” European Journal of Biochemistry, (1981), vol. 117, pp. 161-164.
[cited by applicant]
Wieland, Theodor, “The toxic peptides from Amanita mushrooms,” International Journal of Peptide and Protein Research, (1983), vol. 22, pp. 257-276.
[cited by applicant]
Winkler et al., “EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins,” Molecular Cancer Therapeutics, (Sep. 2009), vol. 8, No. 9, pp. 2674-2683.
[cited by applicant]
Wipf et al., “Synthesis of the Tubuvaline-Tubuphenylalanine (Tuv-Tup) Fragment of Tubulysin,” Organic Letters, (2004), vol. 6, No. 22, pp. 4057-4060.
[cited by applicant]
Wipf et al., “Total Synthesis of N14-Desacetoxytubulysin H,” Organic Letters, (2007), vol. 9, No. 8, pp. 1605-1607.
[cited by applicant]
Wu et al., “Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag,” Proceedings of the National Academy of Sciences, (Mar. 3, 2009), vol. 1…
[cited by applicant]
Yang et al., “Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice,” Proceedings of the National Acade…
[cited by applicant]
Yocum, R. Rogers, “New Laboratory Scale Purification of β-Amanitin from American Amanita phalloides,” Biochemistry, (Sep. 5, 1978), vol. 17, No. 18, pp. 3786-3789.
[cited by applicant]
Zaidi et al., “The Calcitonin Gene Peptides: Biology and Clinical Relevance,” Clinical Reviews in Clinical Laboratory Sciences, (1990), vol. 28, No. 2, pp. 109-174.
[cited by applicant]
Zanotti et al., “Analogs of Amanin,” International Journal of Peptide and Protein Research, (1981), vol. 18, pp. 162-168.
[cited by applicant]
Zanotti et al., “S-deoxo-Abu1, Ile3-amaninamide, an inactive amatoxin analogue,” International Journal of Peptide and Protein Research, (1990), vol. 35, pp. 263-270.
[cited by applicant]
Zanotti et al., “Structure-toxicity relationships in the amatoxin series,” International Journal of Peptide and Protein Research, (1989), vol. 34, pp. 222-228.
[cited by applicant]
Zanotti et al., “Structure-toxicity relationships in the amatoxin series,” International Journal of Peptide and Protein Research, (1992), vol. 40, pp. 551-558.
[cited by applicant]
Zanotti , et al. , “Synthesis of analogues of amaninamide, an amatoxin from the white Amanita virosa mushroom”, International Journal of Peptide and Protein Research, vol. 30 , 1987 , pp. 450-459.
[cited by applicant]
Zanotti et al., “Synthesis of cyclic tryptathionine peptides,” International Journal of Peptide and Protein Research, (1987), vol. 30, pp. 323-329.
[cited by applicant]
Zanotti et al., “Synthetic amatoxin analogues,” International Journal of Peptide and Protein Research, (1988), vol. 32, pp. 9-20.
[cited by applicant]
Zhang et al., “Production and characterization of Amanitin toxins from a pure culture of Amanita exitialis,” FEMS Microbiology Letters, (2005), vol. 252, pp. 223-228.
[cited by applicant]
Zhao et al., “Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer,” Journal of Medicinal Chemistry, (2012), vol. 55, pp. 766-…
[cited by applicant]
Zhao et al., “Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates,” Journal of Medicinal Chemistry, (2011), vol. 54, pp. 3606-3623.
[cited by applicant]
Zhao et al., “Synthesis of a Cytotoxic Amanitin for Biorthogonal Conjugation,” ChemBioChem, (2015), vol. 16, pp. 1420-1425.
[cited by applicant]
Zhelev et al., “Preparation of a β-Amanitin-Concanavalin a Conjugate of Low Toxicity,” Toxicon, (1987) vol. 25, No. 9, pp. 981-987.
[cited by applicant]
Zhou et al., “Cell-Specific Delivery of a Chemotherapeutic to Lung Cancer Cells,” Journal of the American Chemical Society, (2004), vol. 126, pp. 15656-15657.
[cited by applicant]
Zhou et al., “Imaging of nucleolar RNA in living cells using a highly photostable deep-red fluorescent prode,” Biosensors and Bioelectronics, (2015), vol. 68, pp. 189-196.
[cited by applicant]
Zhou et al., “Site-Specific Antibody-Drug Conjugation through Glycoengineering,” Bioconjugate Chemistry, (2014), vol. 25, pp. 510-520.
[cited by applicant]
Zimmerman et al., “Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System,” Bioconjugate Chemistry, (2014), vol. 25, pp. 351-361.
[cited by applicant]
Office Action issued on Jun. 28, 2024, by the U.S. Patent and Trademark Office in related U.S. Appl. No. 17/355,286 (16 pages).
[cited by applicant]
Office Action (Examination report No. 2 for standard patent application) issued Jun. 20, 2023, by the Australian Government, IP Australia in corresponding Australian Patent Application No. 2021266317. (4 pages).
[cited by applicant]
Notice of Allowance and Fee(s) issued Aug. 3, 2023, by the U.S. Patent and Trademark Office in U.S. Appl. No. 17/093,184, U.S. Patent and Trademark Office, Alexandria, VA. (8 pages).
[cited by applicant]
Office Action issued on Dec. 30, 2024, by the U.S. Patent and Trademark Office in related U.S. Appl. No. 17/373,950 (13 pages).
[cited by applicant]